[1]Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increasedlung cancer risk among patients with pulmonary tuberculosis. J Thorac Oncol, 2011, 6(1): 32-37.
[2]Wallis RS, KimP, ColeS, Hanna D, Andrade BB, Maeurer M, et al. Tuberculosisbiomarkersdis-covery: Developments, needs, and challenges. Lancet Infect Dis, 2013,13(4):362-372.
[3]Tomasetti M, Lee W, Santarelli L, Neuzil J. Exosome - derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp Mol Med, 2017, 49( 1) : e285.
[4]Chen X, Xu Y, Liao X, Liao RX , Zhang LP, Niu K, et al. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumour Biol, 2016, 37( 9) : 11927-11936.
[5]Bao Meng, Fu Yurong, Yi Zhengjun. Research progress of microRNA in anti tuberculosis immunity and tuberculosis diagnosis. Chinese Journal of tuberculosis and respiration, 2015, 38(12): 918-921.
[6]Das K, Saikolappan S, Dhandayuthapani S. Differential expression of miRNAs by macrophages infected with virulent and avirulent Mycobacterium tuberculosis. T uberculosis, 2013, 93(Suppl): 47-50.
[7]Münscher A, Prochnow S, Gulati A, Sauter G, Lörincz B, Blessmann M, et al. Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes. Clin Oral Investig, 2019, 23( 1) : 361-367.
[8]Zhang S, Xiao JY, Xie CN, Liu Y, Wang CL Tian YQ. Effect of survivin gene silencing on malignant phenotype of nasopharyngeal carcinoma cell line CNE-2. Journal of Jinan University: Natural Science and medicine, 2011, 32( 6) : 607-610.
[9] Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T -cell assays for the diagnosis of latent tuberculosis infection:moving the research agenda forward. Lancet Infect Dis, 2007, 7(6):428-438.
[10] Jiang W, Shao L, Zhang Y, Zhang S, Meng CY, Xu YY, et al. High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area. BMC Immunol, 2009, 10: 31.
[11] Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect, 2010, 61:133-143.
[12] Abdel-Samea SA, Ismail YM, Fayed SMA, Court R, McCarthy N, Sutcliffe P, et al. Comparative study between using QuantiFERON and tuberculin skin test in diagnosis of Mycobacterium tuberculosis infection. Egyptian Journal of Chest Diseases and Tuberculosis, 2013, 62(1):137-143.
[13] Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung canner (version6). JNCCN, 2015,13(5): 515-524.
[14] National Health and Family Planning Commission of the people's Republic of China. Diagnostic criteria for tuberculosis (WS 288-2017). Electronic Journal of emerging infectious diseases, 2018, 3 (1): 59-61, 2018, 3(1): 59-61.
[15] Tao YH, Yang XL, Jin FX, Lv QQ, Dong HQ. Application of T lymphocyte interferon gamma release test in the diagnosis of tuberculosis. Chinese Journal of nosocomial infection, 2017, 27(18): 4081-4084.
[16]Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer, 2008, 8( 1) : 61-70.
[17] Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma. Nat Med, 1997, 3 (8): 917-921
[18] Roshdy N, Mostafa T. Seminal plasma survivin in fertile and infertile males. J Urol, 2009, 181(3): 1269-1272
[19]Tamm I, Wang Y, Sausville E, Scudiero DA , Vigna N, Oltersdorf T, et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas( CD95) , Bax, caspases, and anticancer drugs. Cancer Res, 1998, 58 ( 23) : 5315-5320.
[20] Cao Y, Dilimulati·Tuohuti, Yang HG. Clinical significance of Survivin and p53 protein expression in non-small cell lung cancer. Chinese Journal of cancer prevention and treatment, 2011, 18( 10) : 773-775.
[21] Zhao SC, Zheng DR. Expression and significance of PPTG, Survivin and bFGF mRNA in non-small cell lung cancer . Journal of Clinical Pulmonary Medicine, 2017, 22(3): 542-545.
[22] Niu YQ, Deng LY, Wang YF. Expression and clinicopathological significance of Sox2 and Survivin in non-small cell lung cancer. Journal of diagnostic pathology, 2015, 22( 10): 594-597.
[23] Liu SJ, Zhang F, Wei W, Tan LZ, Yan J, Wang SQ, et al. Expression of mir-29a-3p and mir-365a-3p in peripheral blood of patients with active pulmonary tuberculosis and latent tuberculosis infection . Clinical study, 2013,10(22):36-38.
[24] Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep, 2009, 10(4):400-405.
[25] Fort A, Borel C, Migliavacca E, Antonarakis SE, Fish RG, Neerman-Arbez M. Regulation of fibrinogen production by microRNAs. Blood, 2010, 116(14):2608-2615.
[26] Wang Y, Liu J, Chen J, Feng T, Guo QL. miR-29a mediates TGFβ 1-induced extracellular matrix synthesis through activation of Wnt /β-catenin pathway in human pulmonary fibroblasts[J]. Technol Health Care, 2015, 23 Suppl 1: S119-125.
[27]Cushing L, Kuang PP, Qian J, Shao FZ, Wu JJ, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol, 2011, 45( 2) : 287-294.
[28] Xiao J, Meng XM, Huang XR, Chung AC, Feng YL, Hui DS, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther, 2012, 20 ( 6) : 1251-1260.
[29] Fu Y, Yi Z, Wu X, Li JH, Xu FL. Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol, 2011,49(12):4246-4251.
[30] Jutta S, Astrid L, Barbara KL, Kamal E, Einspanier R, Sharbati S. Integrated micro-RNA-analysis of human monocyte derived macrophages upon Mycobacterium avium subsp. hominissuis infection . PLOS One,2011,6(5):e20258-e20278
[31] Li TX, He Y, Zhou G, Chen ZZ, Wei CL, Liu M, et al. The value of whole blood interferon gamma release test in the diagnosis of tuberculosis. Chinese Journal of tuberculosis, 2016, 38 (8 ):623- 629.
[32] Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis, 1993, 17(6):968-975.
[33] Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK:two randomised controlled studies. Lancet, 2002, 359(9315):1393-1401.
[34] Wu Y, Li Q, Zhang ZD. The value of interferon gamma release test in the diagnosis of senile pulmonary tuberculosis. Chinese Journal of tuberculosis, 2016, 38 (2):122- 128.
[35]Zeng Y, Li TS, Song MM, Huang L. The value of interferon gamma release test in the diagnosis of active pulmonary tuberculosis. Journal of clinical lung, 2017, 22 ( 5 ):777- 780 .
[36]Huang X, Chen J. Laboratory diagnosis of tuberculouspleual effusion. J Mod Lab Med, 2014,29(1): 97-100.
[37] Zhang SM, Zhou H, Fu YQ, Shen YH, Zhou JY. The clinical value of interferon gamma release test in the diagnosis of active tuberculosis. Chinese Journal of tuberculosis and respiration, 2014, 37 (5):372-373.